<DOC>
	<DOC>NCT01351571</DOC>
	<brief_summary>This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient for up to 4 years.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Advanced and/or metastatic renal cell carcinoma Receiving firstline treatment with Avastin and interferon alpha2a according to standard of care and current local label At least one measurable and nonmeasurable lesion according to RECIST criteria Eastern Cooperative Oncology Group (ECOG) performance status 02 Adequate bone marrow, renal and liver function Contraindications to Avastin and/or interferon alpha2a as per local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>